Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Seoul National University Hospital · Seoul National University · +56 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
237
total citations
- FWCI
- 120.94
- Percentile
- 100%
- References
- 10
Citations per year
Authors
43- DODo‐Youn OhCorresponding
Seoul National University Hospital, Seoul National University
- ARAiwu Ruth He
Georgetown University Medical Center, Georgetown University
- MBMohamed Bouattour
Hôpital Beaujon, Assistance Publique – Hôpitaux de Paris
- TOTakuji Okusaka
Tokyo National Hospital
- SQShukui Qin
Jiangsu Cancer Hospital, Nanjing General Hospital of Nanjing Military Command
Topics & keywords
Topics
Keywords
- Gemcitabine
- Durvalumab
- Interim analysis
- Cisplatin
- Placebo
- Topaz
- Interim
- Medicine
No related works found for this paper.